UNITY Biotechnology Inc
NASDAQ:UBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
UNITY Biotechnology Inc
Cash & Cash Equivalents
UNITY Biotechnology Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
UNITY Biotechnology Inc
NASDAQ:UBX
|
Cash & Cash Equivalents
$8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$5.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$10.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$12B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$18.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
54%
|
CAGR 10-Years
37%
|
|
UNITY Biotechnology Inc
Glance View
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.
See Also
What is UNITY Biotechnology Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
8m
USD
Based on the financial report for Mar 31, 2025, UNITY Biotechnology Inc's Cash & Cash Equivalents amounts to 8m USD.
What is UNITY Biotechnology Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-20%
Over the last year, the Cash & Cash Equivalents growth was 8%. The average annual Cash & Cash Equivalents growth rates for UNITY Biotechnology Inc have been -21% over the past three years , -20% over the past five years .
